AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (2.3 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Clinical Guideline | Open Access

Consensus on Human Epidermal Growth Factor Receptor 2 Overexpression Testing in Pan‐Tumor

Zhe Wang1, Lin Chen2, Wei Rao3, Baoshan Cao4, Muyan Cai5, Xiangshan Fan6, Yuan Ji7, Yuan Li8, Yan Song3, Yan Sun9, Yu Sun10, Chunyan Wu11, Qingxin Xia12, Yanfeng Xi13, Liyan Xue3, Rutie Yin14, Han Liang15( ), Jianming Ying3 ( )
Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, Xi'an, China
Department of Gastrointestinal Surgery, Peking University International Hospital, Beijing, China
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China
Department of Pathology, Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China
Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China
Department of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
Department of Pathology, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
Department of Pathology, Shanxi Province Cancer Hospital, Taiyuan, China
Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China
Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China

Zhe Wang, Lin Chen, and Wei Rao contributed equally to this work.

Show Author Information

Abstract

Human epidermal growth factor receptor 2 (HER2) is a key biomarker and therapeutic target in several malignancies, including breast, gastric, and other solid tumors. Recent advancements in cancer molecular profiling and the Food and Drug Administration's approval of trastuzumab deruxtecan for HER2‐positive pan‐tumor indications have highlighted the broader relevance of HER2 alterations across diverse cancers. However, the lack of standardized guidelines for HER2 testing in a pan‐tumor context creates variability in clinical practice, hindering the optimal implementation of HER2‐targeted therapies beyond traditional indications. To address this gap, a multidisciplinary panel of Chinese experts has developed a consensus providing comprehensive recommendations on diagnostic strategies, testing methodologies, and clinical applications of HER2 overexpression detection. By establishing a unified framework for HER2 overexpression assessment, this consensus aims to enhance the precision of HER2 testing, optimize patient selection for targeted therapies, and improve clinical outcomes across a wide spectrum of HER2 overexpression malignancies.

Graphical Abstract

Electronic Supplementary Material

Download File(s)
cai270060-sup-0001-Supplemental_Table_1.docx (14.5 KB)

References

【1】
【1】
 
 
Cancer Innovation
Article number: e70060

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Wang Z, Chen L, Rao W, et al. Consensus on Human Epidermal Growth Factor Receptor 2 Overexpression Testing in Pan‐Tumor. Cancer Innovation, 2026, 5(2): e70060. https://doi.org/10.1002/cai2.70060

1125

Views

119

Downloads

3

Crossref

2

Web of Science

2

Scopus

Received: 12 August 2025
Revised: 15 December 2025
Accepted: 26 February 2026
Published: 21 April 2026
© 2026 The Author(s). Tsinghua University Press.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.